Abstract
Background
In 2020, the Committee of Clinical Practical Guideline for IgA Nephropathy (IgAN) revised the clinical practice guidelines. Herein, we conducted a questionnaire survey to assess the potential discrepancies between clinical practice guidelines and real-world practice in Japan.
Methods
A web-based survey of members of the Japanese Society of Nephrology was conducted between November 15 and December 28, 2021.
Results
A total of 217 members (internal physicians: 203, pediatricians: 14) responded to the questionnaire. Of these respondents, 94.0% answered that the clinical practice guidelines were referred to “always” or “often.” Approximately 66.4% respondents answered that histological grade (H-Grade) derived from the “Clinical Guidelines for IgA nephropathy in Japan, 3rd version” and the “Oxford classification” were used for pathological classification. Moreover, 73.7% respondents answered that the risk grade (R-grade) derived from the “Clinical Guidelines for IgA nephropathy in Japan, 3rd version” was referred to for risk stratification. The prescription rate of renin–angiotensin system blockers increased based on urinary protein levels (> 1.0 g/day: 88.6%, 0.5–1.0 g/day: 71.0%, < 0.5 g/day: 25.0%). Similarly, the prescription rate of corticosteroids increased according to proteinuria levels (> 1.0 g/day: 77.8%, 0.5–1.0 g/day: 52.8%, < 0.5 g/day: 11.9%). The respondents emphasized on hematuria when using corticosteroids. In cases of hematuria, the indication rate for corticosteroids was higher than in those without hematuria, even if the urinary protein level was 1 g/gCr or less. Few severe infectious diseases or serious deterioration in glycemic control were reported during corticosteroid use.
Conclusion
Our questionnaire survey revealed real-world aspects of IgAN treatment in Japan.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Immunoglobulin A nephropathy (IgAN) is the most common type of chronic glomerulonephritis in Japan. It is a refractory disease, which leads to end-stage renal failure in 30–40% of patients after approximately 20 years [1]. Although various studies have been conducted to date, the use of standard clinical questions in daily clinical practice has not been established because IgAN follows a chronic course with various clinical features. Therefore, accurate medical care for IgAN has not been established.
In 2020, the Research for Intractable Renal Diseases of the Ministry of Health, Labour and Welfare of Japan established the Committee of Clinical Practical Guideline for IgA Nephropathy and published the guideline on its website [2]. Subsequently, a digest version of the guideline was published in 2021 [3]. This guideline explains several treatment options for IgAN and recommends renin–angiotensin system (RAS) blockers and corticosteroids as grade IB (strong recommendation, moderate-quality evidence) based on the results of a systematic review.
Herein, we conducted a questionnaire survey that aimed to assess the extent to which the guidelines were followed in Japan and to reveal several aspects of IgAN treatment.
Methods
In this survey, a web-based questionnaire was distributed to members of the Japanese Society of Nephrology via subscribed mailing list between November 15 and December 28, 2021. It consisted of questions divided into five sections including: (i) baseline characteristics of the responders (Q1–Q7); (ii) “Evidence-Based Clinical Practice Guideline for IgA Nephropathy 2020 [2]” and “Clinical Guidelines for IgA nephropathy in Japan, 3rd version [4]” (Q8–Q10); (iii) selection of the treatment options in detail (Q11–Q21); (iv) practice pattern of RAS blockers and corticosteroids (Q22–Q27); and (v) factors to determine treatment options (Q28–Q31). These questions were deliberated by the specialists of the committee of the guideline for IgA nephropathy though the peer-review from committee members of other disease guideline. Table 1 presents the questionnaire details. If the respondents were treating patients who were newly diagnosed with IgAN, they answered questions after Q11.
Results
A total of 217 members (203 internal physicians and 14 pediatricians) responded to the questionnaire survey.
Adherence to clinical guidelines
204 respondents (94.0%) answered that “evidence-based clinical practice guideline for IgA nephropathy 2020” was referred to “always” or “often” (Fig. 1). Regarding the pathological classifications, 144 respondents (66.4%) answered that both the H-grade derived from “Clinical Guidelines for IgA nephropathy in Japan, 3rd version [4]” and “Oxford classification [5]” were used. Additionally, 60 respondents (27.6%) answered that only the H-grade derived from the “Clinical Guidelines for IgA nephropathy in Japan, 3rd version” was used. Regarding risk stratification, 160 respondents (73.7%) referred to only the R-grade derived from the “Clinical Guidelines for IgA nephropathy in Japan, 3rd version.” Furthermore, 43 respondents (19.8%) referred to both the “Clinical Guidelines for IgA nephropathy in Japan, 3rd version” and “International prediction tool [6].” To determine the remission of IgAN, 140 respondents (79.5%) used the remission criteria proposed by Suzuki et al. [7].
RAS blocker
The prescription rate of RAS blocker according to urinary protein levels is shown in Fig. 2. One hundred fifty-six respondents (88.6%) prescribed RAS blocker for 67% or more cases of urinary protein level > 1 g/day, 125 respondents (71.0%) prescribed RAS blocker for 67% or more cases of urinary protein levels of 0.5–1.0 g/day. Conversely, only 44 respondents (25.0%) prescribed RAS blocker for 67% or more cases of urinary protein level < 0.5 g/day. Regarding prescription of RAS blocker, 148 respondents (84.1%) answered “more important” with eGFR, 124 respondents (70.5%) with histological findings, 169 respondents (96.0%) with blood pressure, and 127 respondents (72.2%) with age (Supplementary Fig. 1).
Corticosteroids
The prescription rate of corticosteroids according to urinary protein levels is shown in Fig. 3. One hundred thirty-seven respondents (77.8%) prescribed corticosteroids for 67% or more cases of urinary protein level > 1 g/day, 93 respondents (52.8%) prescribed corticosteroids for 67% or more cases of urinary protein level of 0.5–1.0 g/day. Conversely, only 21 respondents (11.9%) prescribed corticosteroids for 67% or more cases of urinary protein level < 0.5 g/day. Regarding prescription of corticosteroids, 153 respondents (86.9%) answered “more important” with eGFR, 175 respondents (99.4%) with histological findings, 127 respondents (72.2%) with degree of hematuria, and 149 respondents (84.7%) with age (Supplementary Fig. 2). The frequency of concomitant drug use with corticosteroids is shown in Table 2. The common concomitant drugs at the start of corticosteroid use were anti-osteoporosis drugs (154 respondents, 87.5%), proton pump inhibitors (146 respondents, 83.0%), and sulfamethoxazole/trimethoprim (127 respondents, 72.2%). Table 3 shows the proportion of patients with impaired glucose tolerance and obvious infections due to corticosteroid therapy. One hundred fifty-one respondents (85.8%) answered that impaired glucose tolerance requiring treatment after corticosteroid administration occurred in less than 30% of the cases. Similarly, 166 respondents (94.3%) answered that infectious diseases requiring antimicrobial treatment occurred in less than 10% of the cases.
Tonsillectomy and steroid pulse therapy
In patients with newly diagnosed IgAN, 76 respondents (35.8%) reported performing tonsillectomy with steroid pulse (TSP) therapy in 71% or more cases. The common indications for tonsillectomy were disease activity (147 respondents, 83.5%), history of habitual tonsillitis (136 respondents, 77.3%), and gross hematuria after upper respiratory tract infection (127 respondents, 72.2%). The amount of proteinuria considered when administering corticosteroids varied according to the presence or absence of hematuria (Fig. 4a). Furthermore, Japanese physicians emphasize hematuria as an important factor to determine the indication of corticosteroids and TSP (Fig. 4b). Regarding TSP therapy, 149 respondents (84.7%) answered “very important” with eGFR, 163 respondents (92.6%) with histological findings, 132 respondents (75.0%) with degree of hematuria, and 154 respondents (87.5%) with age (Supplementary Fig. 3).
a Differences in the indication for corticosteroids based on presence or absence of hematuria. There was a trend that presence of the hematuria caused active use of corticosteroids even in case of lower amount of proteinuria. b Importance of hematuria in each treatment option. Japanese physicians emphasize hematuria as an important factor to determine the indication of corticosteroids and TSP
Other drugs including immunosuppressants
One hundred fifty-three respondents (86.9%) reported the use of immunosuppressive drugs other than corticosteroids in fewer than five cases per year. Of these 153 respondents, 113 (64.2%) reported only one case every few years. Sixty-nine respondents (39.2%) prescribed antiplatelet agents in less than 33% of cases, whereas 47 (26.7%) respondents did not prescribe them. Ninety-nine respondents (50.6%) prescribed n-3 fatty acids in less than 33% of cases, whereas 67 respondents (38.1%) did not prescribe them.
Discussion
This study revealed three notable findings. First, the Japanese nephrologists adhered to the guideline recommendations. Second, corticosteroids were relatively safe in Japan because the Japanese nephrologists carefully checked for side effects and used appropriate dosage. Third, the Japanese nephrologists recognized hematuria as a pivotal factor to determine the indication of corticosteroids and TSP.
Pathological examination is essential for establishing a definitive diagnosis of IgAN. Currently, there are two major pathological classifications: the H-grade according to the “Clinical guidelines for IgA nephropathy in Japan, 3rd version [4],” and the “Oxford classification [5].” The H-grade allows for comprehensive assessment of histological severity owing to the use of a lumped system, and the Oxford classification allows for detailed histological findings owing to the use of a split system. Our study demonstrated that 66.4% of the respondents referred to both the H-grade and the Oxford classification. This result was similar to that of a questionnaire survey conducted among councilors of the Japanese Society of Nephrology in 2018 [2]. However, regarding risk stratification, 73.7% of the respondents referred to only the R-grade derived from the “Clinical Guidelines for IgA nephropathy in Japan, 3rd version.” The R-grade determines the risk of end-stage kidney disease (ESKD) by combining the H-grade and clinical severity; consequently, it is easy to use in daily clinical practice. These results suggest that Japanese nephrologists should emphasize the pathological findings and attempt to establish the prognosis of IgAN.
According to the guidelines, RAS blocker are recommended as grade IB (strong recommendation, moderate-quality evidence) based on a systematic review. Several clinical trials on RAS blocker for IgA nephropathy suggested the efficacy of RAS blocker, particularly in patients with urinary protein level of 1.0 g/day or higher [8,9,10]. Conversely, patients with urinary protein level < 0.5 g/day have not been demonstrated adequately [11]. Our study revealed that the prescription rate of RAS blocker differed according to the amount of proteinuria (Fig. 3). These results indicated that the Japanese nephrologists generally follow the guidelines.
The use of corticosteroids is also recommended as grade IB (strong recommendation, moderate-quality evidence) based on a systematic review. In the current study, 77.8% of the respondents prescribed corticosteroids for 67% or more cases of urinary protein level > 1 g/day, as suggested in the guidelines. Although the presence of hematuria was not listed as a criterion for prescribing corticosteroids in the guidelines, the respondents emphasized on hematuria when using corticosteroids (Fig. 4a, b, and Supplementary Fig. 2). Microscopic hematuria in patients with IgAN has been identified as a strong risk factor for progression to ESKD [12, 13]. Additionally, hematuria reportedly reflects disease activity in patients with IgAN based on the multi-hit theory [14, 15]. Thus, Japanese nephrologists should consider disease activity while prescribing corticosteroids.
The adverse effects of corticosteroids include infectious diseases, worsening glycemic control, osteoporosis, and gastritis. In particular, infectious diseases during steroid administration can lead to serious complications, like life-threatening conditions. In a randomized controlled clinical trial that compared supportive care alone (in particular, RAS blocker) and in combination with immunosuppressive therapy for 3 years, severe infection was observed in the supportive care plus immunosuppressive therapy group compared with the supportive care alone group [16]. Another randomized controlled study [17] was terminated because of serious side effects, mostly infectious diseases. However, the dose of corticosteroids in these clinical trials was higher than the dose commonly used in Japan. In 2022, LV et al. reported the results of a clinical trial that included a group receiving a reduced corticosteroid dose [18]. Severe infection requiring hospitalization occurred in five patients in the reduced-dose group (placebo 2) compared with 12 patients in the full-dose group (placebo 1). Our results showed that there were only few cases of severe infectious diseases or serious deterioration in glycemic control. These results indicated that the Japanese nephrologists carefully checked for side effects and used the appropriate doses of corticosteroids.
Hotta et al. first reported TSP in 2001 [19]. Thereafter, several clinical studies, including randomized controlled trials, have been conducted in relation to it [20,21,22,23]. Two nationwide questionnaires, conducted in 2006 [24] and 2008 [25], indicated that TSP was the standard treatment for adult patients with IgAN in Japan. Then KDIGO guidelines described tonsillectomy would be applied only for Japanese patient with IgAN [26]. In this study, in patients with newly diagnosed IgAN, 35.8% of the respondents would perform TSP in more than 71% of patients. However, treatment protocol, especially the number of steroid pulses therapy combined with tonsillectomy, is highly variable in each institution [27, 28], and indication of TSP for elderly or child patients with IgA nephropathy are under discussion [29, 30].
The degrees of proteinuria and hematuria are commonly used as prognostic indicators during the course of treatment [13, 31,32,33]. In 2013, the Special IgA Nephropathy Study Group in Progressive Renal Diseases Research, affiliated with the Research on Intractable Diseases by the Ministry of Health, Labor, and Welfare in Japan, proposed new remission criteria for IgAN based on a nationwide awareness survey. Subsequently, Matsuzaki et al. reported the utility of the criteria in a single-center longitudinal cohort study [34]. In the current study, 79.5% of the respondents used the criteria to determine remission of IgAN. Since IgAN has a long-term clinical course, the concept of remission may become more important in the future.
This study had several limitations. First, it was based on a questionnaire administered to the members of the Japanese Society of Nephrology rather than a collection of actual patient data. Thus, we could not assess the clinical indicators including candidate molecules of pathogenesis of IgAN. Second, there was social-desirability bias because this questionnaire was distributed via subscribed mailing list in Japanese society of nephrology. Third, this questionnaire was intended for nephrologists resulted in possible underestimation of evidence-practice gap. Fourth, over 90% of the respondents were physicians, with only a few pediatricians. Therefore, the applicability of our results is likely limited to adult patients. To overcome these limitations, further investigation based on the nationwide-multicenter kidney disease registry included regional information, scale of facilities, and candidate molecules was needed.
Conclusion
This questionnaire survey elucidated real-world aspects regarding the treatment for IgAN in Japan. Our findings may aid further research to determine standard treatments.
References
Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on progressive renal diseases. Am J Kidney Dis. 1997;29:526–32. https://doi.org/10.1016/s0272-6386(97)90333-4.
Official Website of the Grant in Aid for Intractable Renal Diseases Research, Research on rare and intractable diseases, Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan. Evidence‑based clinical practice guideline for IgA nephropathy 2020. http://jin-shogai.jp/policy/pdf/IgA_2020.pdf. Accessed 24 Nov 2022
Suzuki H, Kikuchi M, Koike K, Komatsu H, Matsuzaki K, Takahashi K, Ichikawa D, Okabe M, Obata Y, Katafuchi R, Kihara M, Kohatsu K, Sasaki T, Shimizu A, Nakanishi K, Fukuda A, Miyazaki Y, Muto M, Yanagawa H, Suzuki Y, Fujimoto S, Furuichi K, Okada H, Narita I, Committee of Clinical Practical Guideline for IgA Nephropathy 2020. A digest from evidence-based clinical practice guideline for IgA nephropathy 2020. Clin Exp Nephrol. 2021;25:1269–76. https://doi.org/10.1007/s10157-021-02095-8.
Clinical guides for immunoglobulin A (IgA) nephropathy in Japan, third version. Nihon Jinzo Gakkai Shi. 2011;53(2):123–35.
Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, Cook HT, Freehally J, Robert ISD, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D’Agati V, D’Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PKT, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–45. https://doi.org/10.1038/ki.2009.243.
Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Er L, Espino-Hernandez G, Kim SJ, Reich HN, Feehally J, Cattran DC, International IgA Nephropathy Network. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179:942–52. https://doi.org/10.1001/jamainternmed.2019.0600.
Suzuki Y, Matsuzaki K, Suzuki H, Sakamoto N, Joh K, Kawamura T, Tomino Y, Matsuo S. Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol. 2014;18:481–6. https://doi.org/10.1007/s10157-013-0849-x.
Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis. 2000;35:1155–65. https://doi.org/10.1016/s0272-6386(00)70054-0.
Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC, HKVIN Study Group. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751–60. https://doi.org/10.1053/j.ajkd.2006.01.017.
Woo KT, Lau YK, Zhao Y, Liu FE, Tan HB, Tan EK, Stephanie FC, Chan CM, Wong KS. Disease progression, response to ACEI/ATRA therapy and influence of ACE gene in IgA nephritis. Cell Mol Immunol. 2007;4:227–32.
Li PKT, Kwan BCH, Chow KM, Leung CB, Szeto CC. Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor. Am J Med. 2013;126:162–8. https://doi.org/10.1016/j.amjmed.2012.06.028.
Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant. 2009;24:3068–74. https://doi.org/10.1093/ndt/gfp273.
Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, Liu Z. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27:1479–85. https://doi.org/10.1093/ndt/gfr527.
Suzuki Y, Matsuzaki K, Suzuki H, Okazaki K, Yanagawa H, Ieiri N, Sato M, Sato T, Taguma Y, Matsuoka J, Horikoshi S, Novak J, Hotta O, Tomino Y. Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clin Exp Nephrol. 2014;18:770–7. https://doi.org/10.1007/s10157-013-0921-6.
Suzuki H. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clin Exp Nephrol. 2019;23:26–31. https://doi.org/10.1007/s10157-018-1582-2.
Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J, STOP-IgAN Investigators. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373:2225–36. https://doi.org/10.1056/NEJMoa1415463.
Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, Monaghan H, Zhao M, Barbour S, Reich H, Cattran D, Glassock R, Levin A, Wheeler D, Woodward M, Billot L, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Wang HY, Perkovic V, TESTING Study Group. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318:432–42. https://doi.org/10.1001/jama.2017.9362.
Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Jardine MJ, Reich HN, Cattran D, Glassock R, Levin A, Wheeler DC, Woodward M, Billot L, Stepien S, Rogers K, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V, TESTING Study Group. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327:1888–98. https://doi.org/10.1001/jama.2022.5368.
Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, Abe K, Taguma Y. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43. https://doi.org/10.1053/ajkd.2001.27690.
Sato M, Hotta O, Tomioka S, Horigome I, Chiba S, Miyazaki M, Noshiro H, Taguma Y. Cohort study of advanced IgA nephropathy: efficacy and limitations of corticosteroids with tonsillectomy. Nephron Clin Pract. 2003;93:c137–45. https://doi.org/10.1159/000070233.
Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3:1301–7. https://doi.org/10.2215/FCJN.00310108.
Ieiri N, Hotta O, Sato T, Taguma Y. Significance of the duration of nephropathy for achieving clinical remission in patients with IgA nephropathy treated by tonsillectomy and steroid pulse therapy. Clin Exp Nephrol. 2012;16:122–9. https://doi.org/10.1007/s10157-011-0530-1.
Kawamura T, Yoshimura M, Miyazaki Y, Okamoto H, Kimura K, Hirano K, Matsushima M, Utsunomiya Y, Ogura M, Yokoo T, Okonogi H, Ishii T, Hamaguchi A, Ueda H, Furusu A, Horikoshi S, Suzuki Y, Shibata T, Yasuda T, Shirai S, Imasawa T, Kanozawa K, Wada A, Yamaji I, Miura N, Imai H, Kasai K, Soma J, Fujimoto S, Matsuo S, Tomino Y, Special IgA Nephropathy Study Group. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant. 2014;29:1546–53. https://doi.org/10.1093/ndt/gfu020.
Miura N, Imai H, Kikuchi S, Hayashi S, Endoh M, Kawamura T, Tomino Y, Moriwaki K, Kiyomoto H, Kohagura K, Nakazawa E, Kusano E, Mochizuki T, Nomura S, Sasaki T, Kashihara N, Soma J, Tomo T, Nakabayashi I, Yoshida M, Watanabe T. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460–6. https://doi.org/10.1007/s10157-009-0179-1.
Matsuzaki K, Suzuki Y, Nakata J, Sakamoto N, Horikoshi S, Kawamura T, Matsuo S, Tomino Y. Nationwide survey on current treatments for IgA nephropathy in Japan. Clin Exp Nephrol. 2013;17:827–33. https://doi.org/10.1007/s10157-013-0779-7.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO. Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;2021(100):S1–276.
Moriyama T, Kataoka H, Nitta K, Hirano K, Matsuzaki K, Yasuda T, Yasuda Y, Koike K, Maruyama S, Yokoo T, Matsuo S, Kawamura T, Suzuki Y. Impact of the number of steroid pulses in tonsillectomy combined with steroid pulse therapy: a nationwide retrospective study in Japan. Clin Exp Nephrol. 2021;25(1):19–27. https://doi.org/10.1007/s10157-020-01960-2.
Toda M, Kume A, Hara M, Kimura H, Nakamura Y, Okumura K, Beppu H, Nakamura Y, Ogawa H, Kamei Y, Ishiwatari A, Kawanishi T, Ogawa T, Abe Y, Endo M, Wakai S. Efficacy and limitations of additional steroid pulse therapy in IgA nephropathy patients whose hematuria did not remit on tonsillectomy and protocol steroid pulse therapy. Clin Exp Nephrol. 2022;26(9):859–66. https://doi.org/10.1007/s10157-022-02226-9.
Takashima T, Mizuta M, Ikeda Y, Fukuda M, Miyazono M. Do you recommend tonsillectomy for elderly patients with IgA nephropathy? Clin Exp Nephrol. 2021;25(7):804–6. https://doi.org/10.1007/s10157-021-02043-6.
Kawasaki Y. Treatment strategy with multidrug therapy and tonsillectomy pulse therapy for childhood-onset severe IgA nephropathy. Clin Exp Nephrol. 2022;26(6):501–11. https://doi.org/10.1007/s10157-022-02187-z.
Sevillano AM, Gutiérrez E, Yuste C, Cavero T, Mérida E, Rodríguez P, García A, Morales E, Fernández C, Martínez MA, Moreno JA, Praga M. Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol. 2017;28(10):3089–99. https://doi.org/10.1681/ASN.2017010108.
Yu GZ, Guo L, Dong JF, Shi SF, Liu LJ, Wang JW, Sui GL, Zhou XJ, Xing Y, Li HX, Lv JC, Zhang H. Persistent hematuria and kidney disease progression in IgA nephropathy: a cohort study. Am J Kidney Dis. 2020;76(1):90–9. https://doi.org/10.1053/j.ajkd.2019.11.008.
He P, Wang H, Huang C, He L. Hematuria was a high risk for renal progression and ESRD in immunoglobulin a nephropathy: a systematic review and meta-analysis. Ren Fail. 2021;43(1):488–99. https://doi.org/10.1080/0886022X.2021.1879852.
Matsuzaki K, Suzuki H, Kawamura T, Tomino Y, Suzuki Y. Utility of remission criteria for the renal prognosis of IgA nephropathy. Clin Exp Nephrol. 2021;25:988–95. https://doi.org/10.1007/s10157-021-02069-w.
Acknowledgements
We gratefully acknowledge the members of the Japanese Society of Nephrology who responded to the questionnaire. This study was supported in part by a Grant-in-Aid for Intractable Renal Diseases Research, Research on Rare and Intractable Diseases, and Health and Labour Sciences Research Grants from the Ministry of Health, Labour, and Welfare of Japan (20FC1045).
Author information
Authors and Affiliations
Consortia
Contributions
KM and HS had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: KM, HS, MK, KK, HK, KT. Acquisition, analysis, or interpretation of data: KM, HS, MK, KK, HK, KT. Drafting of the manuscript: KM. Critical revision of the manuscript for important intellectual content: HS, MK, KK, HK, KT, IN, HO. Statistical analysis: KM. Obtained funding: HS, IN, HO. Administrative, technical, or material support: KM. Supervision: HS, IN, HO
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict interests.
Ethical approval
This study was an anonymous survey of healthcare professionals to describe the practice of IgA nephropathy and was considered outside the scope of the ethical review according to the Ethical Guidelines for Medical and Biological Research Involving Human Subjects (Jpn J Clin Oncol. 2022; 52: 539–44).
Informed consent
The possibility of academic publication of the survey results was described at the beginning of the questionnaire, and only those who provided consent to complete the survey were included.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
10157_2023_2396_MOESM1_ESM.pptx
Supplementary file1 Supplementary Fig. 1: Important factors for use of RAS blocker. Supplementary Fig. 2: Important factors for use of corticosteroids. Supplementary Fig. 3: Important factors to determine indication of tonsillectomy with steroid pulse therapy (PPTX 58 KB)
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Matsuzaki, K., Suzuki, H., Kikuchi, M. et al. Current treatment status of IgA nephropathy in Japan: a questionnaire survey. Clin Exp Nephrol 27, 1032–1041 (2023). https://doi.org/10.1007/s10157-023-02396-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-023-02396-0